22nd Century Group Stock Forecast, Price & News

+0.02 (+0.45 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.66 million shs
Average Volume4.01 million shs
Market Capitalization$681.97 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive XXII News and Ratings via Email

Sign-up to receive the latest news and ratings for 22nd Century Group and its competitors with MarketBeat's FREE daily newsletter.

22nd Century Group logo

About 22nd Century Group

22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets. It develops very low nicotine content tobacco and cigarette products under the Moonlight and Moonlight Menthol names; and SPECTRUM research cigarettes for use in independent clinical studies. 22nd Century Group, Inc. has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.56 out of 5 stars

Consumer Staples Sector

239th out of 312 stocks

Cigarettes Industry

7th out of 11 stocks

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

22nd Century Group (NYSEAMERICAN:XXII) Frequently Asked Questions

Is 22nd Century Group a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 22nd Century Group in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" 22nd Century Group stock.
View analyst ratings for 22nd Century Group
or view top-rated stocks.

What stocks does MarketBeat like better than 22nd Century Group?

Wall Street analysts have given 22nd Century Group a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but 22nd Century Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is 22nd Century Group's next earnings date?

22nd Century Group is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for 22nd Century Group

How were 22nd Century Group's earnings last quarter?

22nd Century Group, Inc. (NYSEAMERICAN:XXII) announced its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). 22nd Century Group had a negative trailing twelve-month return on equity of 41.31% and a negative net margin of 74.35%.
View 22nd Century Group's earnings history

Who are 22nd Century Group's key executives?

22nd Century Group's management team includes the following people:
  • Mr. James A. Mish, Chief Exec. Officer (Age 57, Pay $1.14M)
  • Mr. Michael J. Zercher, Pres & COO (Age 50, Pay $764.5k)
  • Mr. John E. Franzino, VP of Admin., CFO & Treasurer (Age 64, Pay $408.9k)
  • Ms. Mei Kuo, Director of Communications & Investor Relations
  • Mr. Steven Przybyla, Gen. Counsel & Corp. Sec.
  • Mr. Henry Sicignano III, M.B.A., MBA, Consultant (Age 53)
  • Mr. James C. Morrison, Technical Advisor & Regulatory Affairs Consultant

Who are some of 22nd Century Group's key competitors?

What other stocks do shareholders of 22nd Century Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 22nd Century Group investors own include KushCo (KSHB), OrganiGram (OGI), Medical Marijuana (MJNA), Cara Therapeutics (CARA), GB Sciences (GBLX), (CGC), Auxly Cannabis Group (CBWTF), MariMed (MRMD), MassRoots (MSRT) and American Cannabis (AMMJ).

What is 22nd Century Group's stock symbol?

22nd Century Group trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XXII."

Who are 22nd Century Group's major shareholders?

22nd Century Group's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.74%), Millennium Management LLC (1.32%), Mirae Asset Global Investments Co. Ltd. (0.90%), Geode Capital Management LLC (0.75%), Renaissance Technologies LLC (0.48%) and Quinn Opportunity Partners LLC (0.33%). Company insiders that own 22nd Century Group stock include Clifford B Fleet, James A Mish, Nora B Sullivan and Roger D O'brien.
View institutional ownership trends for 22nd Century Group

Which major investors are selling 22nd Century Group stock?

XXII stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, IHT Wealth Management LLC, Citigroup Inc., Mirae Asset Global Investments Co. Ltd., UBS Group AG, and Bank of New York Mellon Corp.
View insider buying and selling activity for 22nd Century Group
or view top insider-selling stocks.

Which major investors are buying 22nd Century Group stock?

XXII stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Quinn Opportunity Partners LLC, HRT Financial LP, Cubist Systematic Strategies LLC, Morgan Stanley, Goldman Sachs Group Inc., and Barclays PLC. Company insiders that have bought 22nd Century Group stock in the last two years include Clifford B Fleet, James A Mish, Nora B Sullivan, and Roger D O'brien.
View insider buying and selling activity for 22nd Century Group
or or view top insider-buying stocks.

How do I buy shares of 22nd Century Group?

Shares of XXII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 22nd Century Group's stock price today?

One share of XXII stock can currently be purchased for approximately $4.47.

How much money does 22nd Century Group make?

22nd Century Group has a market capitalization of $681.97 million and generates $28.10 million in revenue each year. The biotechnology company earns $-19,710,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

How many employees does 22nd Century Group have?

22nd Century Group employs 67 workers across the globe.

What is 22nd Century Group's official website?

The official website for 22nd Century Group is www.xxiicentury.com.

Where are 22nd Century Group's headquarters?

22nd Century Group is headquartered at 9530 Main St, CLARENCE, NY 14031-1915, United States.

How can I contact 22nd Century Group?

22nd Century Group's mailing address is 9530 Main St, CLARENCE, NY 14031-1915, United States. The biotechnology company can be reached via phone at +1-716-2701523.

This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.